These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17666825)

  • 1. Bioequivalence of marketed transdermal delivery systems for tulobuterol.
    Tojo K; Hikima T
    Biol Pharm Bull; 2007 Aug; 30(8):1576-9. PubMed ID: 17666825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin permeability of tulobuterol in two transdermal formulations and their followability.
    Takizawa Y; Goto T; Sato S; Ohmori N; Mori K; Shimada Y; Chen K; Miyagi T; Fukai F
    Drug Discov Ther; 2017 Nov; 11(5):253-258. PubMed ID: 29021505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application.
    Nakamura A; Mori D; Tojo K
    Chem Pharm Bull (Tokyo); 2012; 60(3):300-5. PubMed ID: 22382408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of monolithic matrix patch system containing tulobuterol.
    Rhee YS; Kwon SY; Park CW; Choi NY; Byun WJ; Chi SC; Park ES
    Arch Pharm Res; 2008 Aug; 31(8):1029-34. PubMed ID: 18787793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Model analysis of tulobuterol patch formulations to explain the influence of drug release rate and transdermal transfer rate on the plasma concentration profile].
    Watanabe T; Satoh H; Hori S; Miki A; Ohtani H; Sawada Y
    Yakugaku Zasshi; 2011; 131(10):1483-92. PubMed ID: 21963976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of skin permeation profiles between brand and generic tulobuterol patches.
    Yoshihara S; Fukuda H; Abe T; Arisaka O
    Biol Pharm Bull; 2010; 33(10):1763-5. PubMed ID: 20930390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation.
    Ahmed S; Imai T; Otagiri M
    Pharm Res; 1996 Oct; 13(10):1524-9. PubMed ID: 8899845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects
.
    Park SI; Kim BH
    Int J Clin Pharmacol Ther; 2018 Aug; 56(8):381-386. PubMed ID: 29932416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation.
    Uematsu T; Nakano M; Kosuge K; Kanamaru M; Nakashima M
    Eur J Clin Pharmacol; 1993; 44(4):361-4. PubMed ID: 8099880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Drug-in-Adhesive Patch with a Honeycomb Film as a Backing Layer.
    Suzuki T; Sakisako Y; Kurihara Y; Aoki T; Kanematsu T; Todo H; Sugibayashi K
    Chem Pharm Bull (Tokyo); 2018; 66(9):851-858. PubMed ID: 30175741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical optimization of transdermal drug delivery system of terbutaline sulfate by factorial analysis.
    Manna A; Ghosh I; Sen N; Thakur RS; Ghosh LK; Gupta BK
    Boll Chim Farm; 2000; 139(1):34-40. PubMed ID: 10829551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatex-type transdermal delivery systems through mouse and human cadaver skins.
    Panigrahi L; Pattnaik S; Ghosal SK
    AAPS PharmSciTech; 2005 Sep; 6(2):E167-73. PubMed ID: 16353974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method for predicting steady-state rate of skin penetration in vivo.
    Tojo K; Lee AC
    J Invest Dermatol; 1989 Jan; 92(1):105-8. PubMed ID: 2909621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
    Aboofazeli R; Zia H; Needham TE
    Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
    Kato H; Nagata O; Yamazaki M; Suzuki T; Nakano Y
    Yakugaku Zasshi; 2002 Jan; 122(1):57-69. PubMed ID: 11828751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers.
    Kubota K; Shibata A; Yamaguchi T
    Eur J Pharm Sci; 2016 Apr; 86():75-83. PubMed ID: 26965004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin permeation of ketotifen applied from stick-type formulation.
    Kimura C; Nakanishi T; Tojo K
    Eur J Pharm Biopharm; 2007 Sep; 67(2):420-4. PubMed ID: 17433642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of nalbuphine and its prodrugs across skin by passive diffusion and iontophoresis.
    Sung KC; Fang JY; Hu OY
    J Control Release; 2000 Jun; 67(1):1-8. PubMed ID: 10773323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
    Yang Z; Teng Y; Wang H; Hou H
    Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a tulobuterol patch with improved mechanical properties: effect of transdermal permeation enhancers on the release process of metal ligand-based acrylic pressure-sensitive adhesives.
    Nan L; Song H; Wang H; Mi R; Wang X; Fang L
    Drug Deliv Transl Res; 2024 Mar; 14(3):802-811. PubMed ID: 38082031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.